IDEXX Laboratories, Inc. (IDXX): Price and Financial Metrics
IDEXX Laboratories, Inc. (IDXX)
Today's Latest Price: $493.50 USD
Updated Jan 21 12:34pm
Add IDXX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 186 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
IDXX Stock Summary
- With a market capitalization of $42,226,859,031, Idexx Laboratories Inc has a greater market value than 94.49% of US stocks.
- Idexx Laboratories Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 93.68% of US listed stocks.
- With a one year PEG ratio of 646.5, Idexx Laboratories Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 94% of US stocks.
- If you're looking for stocks that are quantitatively similar to Idexx Laboratories Inc, a group of peers worth examining would be BAX, A, ALGN, EBAY, and CSGP.
- Visit IDXX's SEC page to see the company's official filings. To visit the company's web site, go to www.idexx.com.
IDXX Stock Price Chart Interactive Chart >
IDXX Price/Volume Stats
| Current price | $493.50 | 52-week high | $516.86 |
| Prev. close | $495.04 | 52-week low | $168.65 |
| Day low | $487.48 | Volume | 72,024 |
| Day high | $496.45 | Avg. volume | 369,792 |
| 50-day MA | $473.25 | Dividend yield | N/A |
| 200-day MA | $380.07 | Market Cap | 42.10B |
IDEXX Laboratories, Inc. (IDXX) Company Bio
IDEXX Laboratories develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. The company was founded in 1983 and is based in Westbrook, Maine.
IDXX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $493.50 | $123.52 | -75% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Idexx Laboratories Inc. To summarize, we found that Idexx Laboratories Inc ranked in the 22th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Idexx Laboratories Inc, consider:
- The stock's equity weight, or the proportion of capital from equity relative to debt, is 98. Notably, its equity weight is greater than 81.49% of US equities in the Healthcare sector yielding a positive free cash flow.
- The business' balance sheet suggests that 2% of the company's capital is sourced from debt; this is greater than only 10.9% of the free cash flow producing stocks we're observing.
- IDXX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 48.48% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -76% |
| 1% | -75% |
| 2% | -75% |
| 3% | -75% |
| 4% | -75% |
| 5% | -74% |
BSX, HZNP, MDT, NUVA, and PRGO can be thought of as valuation peers to IDXX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...